Cases
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH)
Securities Class Action
Overview
Overview
- Date:
- 2/14/2017
- Company Name:
- Anthera Pharmaceuticals, Inc.
- Stock Symbol:
- ANTH
- Class Period:
- FROM 2/10/2015 TO 12/27/2016
- Status:
- Closed/Complete
- Court:
- U.S. District Court: Northern California
NEW YORK, February 14, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who acquired Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) securities between February 10, 2015 and December 27, 2016 (the “Class Period”).
The complaint alleges that throughout the Class Period, Anthera made materially false and/or misleading statements concerning the potential efficacy and success of its Solution Study and CHABLIS-SC1 clinical trials, as the Company failed to disclose that: (i) patients were not improving in the CHABLIS-SC1 clinical trial; and (ii) there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses.
On November 10, 2016, the Company issued a press release announcing that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of SLE failed to meet its primary endpoint. Following this news, shares of Anthera fell approximately 32% to close at $1.90 on November 10, 2016. Then on December 27, 2016, the Company issued another press release, announcing that the Solution clinical study in cystic fibrosis patients with EPI missed the CFA non-inferiority margin of the primary modified Intent to Treat. Following this news, shares of Anthera fell approximately 63% to close at $0.74 on December 28, 2016.
If you purchased or otherwise acquired Anthera securities during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, Anthera made materially false and/or misleading statements concerning the potential efficacy and success of its Solution Study and CHABLIS-SC1 clinical trials, as the Company failed to disclose that: (i) patients were not improving in the CHABLIS-SC1 clinical trial; and (ii) there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses.
On November 10, 2016, the Company issued a press release announcing that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of SLE failed to meet its primary endpoint. Following this news, shares of Anthera fell approximately 32% to close at $1.90 on November 10, 2016. Then on December 27, 2016, the Company issued another press release, announcing that the Solution clinical study in cystic fibrosis patients with EPI missed the CFA non-inferiority margin of the primary modified Intent to Treat. Following this news, shares of Anthera fell approximately 63% to close at $0.74 on December 28, 2016.
If you purchased or otherwise acquired Anthera securities during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.